Amro Al-Astal, MD
Pulmonary Disease · Huntington, WVNPI 1396193769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by United Therapeutics Corporation at 42.9% of the total. Reporting peaked in 2023 at $404 and has fallen 65.6% since, to $139 in 2025. That places this record below the midpoint for pulmonary disease clinicians in WV, where the typical reported total is $1,097.
Across 24 payments — averaging $44.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$458
- Actelion Pharmaceuticals US, Inc.$431
- Pulmonx Corporation$179
Across 14 payments — averaging $16,414 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$230K
What the payments were for
- Food & beverage$97091%
- Education$999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 10 | $458 |
| Actelion Pharmaceuticals US, Inc. | 12 | $431 |
| Pulmonx Corporation | 2 | $179 |
How this compares
$1,069 in reported general payments places this provider in the 45th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 97 | $2,316,486 |
| OpsumitMacitentan | 32 | $405,068 |
| OfevNintedanib Esylate | 22 | $268,705 |
| Ambrisentan | 65 | $193,163 |
| Bosentan | 12 | $58,009 |
| Sildenafil Citrate | 37 | $36,585 |
| Spiriva HandihalerTiotropium Bromide | 19 | $17,872 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $15,635 |
| Tadalafil | 24 | $10,747 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,530 |
| Mycophenolate Mofetil | 35 | $4,105 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,968 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,198 |
| Spironolactone | 49 | $166 |
| Montelukast Sodium | 20 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Bosentan | $431 | $463,07744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Huntington
- Yousef ShweihatHuntington$6K
- Fadi AlkhankanHuntington$5K
- Julian Lopez GarciaHuntington$5K
- Sigurdur SigurdarsonHuntington$5K
- Imran KhawajaHuntington$2K
- Melinda BeckerHuntington$776
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.